AI assistant
SCYNEXIS INC — Director's Dealing 2014
Jun 20, 2014
34648_dirs_2014-06-20_fddeb2bd-22fb-4521-a537-0a3b88baf41d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SCYNEXIS INC (SCYX)
CIK: 0001178253
Period of Report: 2014-06-18
Reporting Person: Sable Carole (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-06-18 | Stock Option (right to buy) | $9.64 | A | 46636 | Acquired | 2024-06-17 | Common Stock (46636) | Direct |
| 2014-06-18 | Stock Option (right to buy) | $10.00 | D | 46636 | Disposed | 2024-01-15 | Common Stock (46636) | Direct |
| 2014-06-18 | Stock Option (right to buy) | $9.64 | A | 26970 | Acquired | 2024-06-17 | Common Stock (26970) | Direct |
Footnotes
F1: The option vests and becomes exercisable with respect to 25% of the total number of underlying shares on the first anniversary of the vesting commencement date and with respect to an additional 6.25% quarterly thereafter for the following 12 quarters.
F2: In connection with the re-pricing of the option, the option was further amended to provide that the term of the option shall be extended until June 17, 2024. In connection with the amendments, the original option is deemed canceled and replaced with a new option.
F3: The option vests in 48 equal monthly installments from the grant date of June 18, 2014.